Beam Therapeutics (BEAM) Operating Income (2019 - 2025)
Historic Operating Income for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$126.8 million.
- Beam Therapeutics' Operating Income fell 1906.69% to -$126.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$466.3 million, marking a year-over-year decrease of 15525.67%. This contributed to the annual value of -$415.6 million for FY2024, which is 13546.93% down from last year.
- Latest data reveals that Beam Therapeutics reported Operating Income of -$126.8 million as of Q3 2025, which was down 1906.69% from -$120.2 million recorded in Q2 2025.
- Beam Therapeutics' Operating Income's 5-year high stood at $132.9 million during Q4 2023, with a 5-year trough of -$200.4 million in Q1 2021.
- Over the past 5 years, Beam Therapeutics' median Operating Income value was -$100.0 million (recorded in 2024), while the average stood at -$88.9 million.
- Its Operating Income has fluctuated over the past 5 years, first crashed by 60665.84% in 2021, then surged by 24930.38% in 2023.
- Over the past 5 years, Beam Therapeutics' Operating Income (Quarter) stood at -$63.5 million in 2021, then tumbled by 40.17% to -$89.0 million in 2022, then skyrocketed by 249.3% to $132.9 million in 2023, then plummeted by 175.3% to -$100.0 million in 2024, then decreased by 26.76% to -$126.8 million in 2025.
- Its Operating Income stands at -$126.8 million for Q3 2025, versus -$120.2 million for Q2 2025 and -$119.3 million for Q1 2025.